Protege la salud cognitiva desde hoy

FontUp® ha demostrado beneficios cognitivos en personas con riesgo de desarrollar Alzheimer¹

¹Forcano L, et al. The Journal of Prevention of Alzheimer’s Disease. 2025
Comprar FontUp®

Protect your cognitive health starting today.

FontUp® has demonstrated cognitive benefits in people at risk of developing Alzheimer's¹

¹ Forcano L, et al. The Journal of Prevention of Alzheimer's Disease. 2025
Buy FontUp®

Alzheimer's disease begins years before diagnosis.

The processes that lead to cognitive decline can begin years before a clinical diagnosis is made. During this time, the brain undergoes progressive changes that do not yet result in a clear functional limitation.

This early stage is known as Subjective Cognitive Impairment and represents a key opportunity to start taking care of cognitive health.

Signs to pay attention to

Learn more

The first cognitive changes can manifest subtly in daily life. Subjective cognitive decline is the individual's perception of a worsening of cognitive abilities that cannot be explained by transient factors such as stress, lack of sleep, or specific emotional situations, and that is not yet reflected in routine clinical tests. Among the most frequent signs are:

Memory complaints

Difficulty concentrating

Changes in cognitive performance

Difficulty in executive functions

In addition, there are risk factors that can increase the likelihood of developing Alzheimer's disease later in life. These include a family history of Alzheimer's, high blood pressure, diabetes, obesity, sleep disorders, and being over 60 years of age.

Discover FontUp®

Complement to early intervention in subjective cognitive decline

FontUp® has been tested in the PENSA clinical study where it has been shown to improve cognitive performance and reduce the risk of dementia in people at risk of developing Alzheimer's.

Buy FontUp®
Clinically proven
·
Improved cognitive performance
·
It reduces the risk of dementia
·
Clinically proven
·
Improved cognitive performance
·
It reduces the risk of dementia
·
Clinically proven
·
Improved cognitive performance
·
It reduces the risk of dementia
·
Clinically proven
·
Improved cognitive performance
·
It reduces the risk of dementia
·
Clinically proven
·
Improved cognitive performance
·
It reduces the risk of dementia
·
Clinically proven
·
Improved cognitive performance
·
It reduces the risk of dementia
·

Science and first-person experience

“The focus must be on prevention. If we want to tackle the issue of neurodegenerative diseases, it's with prevention, prevention, and prevention.”

Dr. Rafael de la Torre, coordinator of the PENSA study and researcher at IMIM.

“I am a new person, my life has changed. All my worries have vanished.”

Participant in the PENSA Study

"Not only does it significantly improve cognition, but there is also a reduction in the risk of dementia."

Dr. Rafael de la Torre, coordinator of the PENSA study and researcher at IMIM.